Form 4: Director Dai Acquires Astrana Health Restricted Stock

Astrana Health Director Weili Dai acquired 4,525 restricted shares of common stock, vesting by June 2027, under the company's 2024 Equity Incentive Plan.

Summary

• Weili Dai, a Director and 10% Owner of Astrana Health, Inc. (ASTH), acquired 4,525 shares of common stock on June 10, 2026.
• These shares are restricted stock granted pursuant to the Issuer's 2024 Equity Incentive Plan.
• The restricted shares will vest on the earlier of June 10, 2027, or the date of the Issuer's 2027 annual meeting of stockholders.
• The acquisition price for these shares was $0, indicating a grant rather than a purchase.
• Following this transaction, Dai beneficially owns a total of 18,188 shares of common stock, which includes the newly acquired restricted stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as an insider increasing their stake, even through a grant, generally indicates confidence in the company's future prospects and aligns director interests with shareholders.

Positives

• Director Weili Dai increased her beneficial ownership in Astrana Health by acquiring 4,525 restricted shares, signaling continued alignment with shareholder interests.
• The grant is part of the company's 2024 Equity Incentive Plan, indicating ongoing efforts to incentivize key personnel and align their long-term interests with the company's success.

Negatives

• No explicit negatives are present in this Form 4 filing, which primarily reports an insider equity transaction.

Risks

• The value of the restricted stock is subject to the future performance of Astrana Health's common stock until vesting.
• Vesting is contingent on continued service until the earlier of June 10, 2027, or the date of the Issuer's 2027 annual meeting of stockholders, posing a forfeiture risk if the reporting person's service ceases before then.

Future Outlook

The vesting schedule for the restricted shares, set for the earlier of June 10, 2027, or the 2027 annual meeting, indicates a future milestone for the reporting person's equity compensation and continued alignment with the company's long-term performance.

Industry Context

StockSavvy.ai notes that equity grants to directors are a standard practice across industries, including healthcare, to align leadership incentives with long-term shareholder value. Such grants often reflect confidence in the company's future performance and serve as a retention mechanism for key personnel.

Comparison to Industry Standards

• Equity incentive plans and restricted stock grants are common compensation tools across publicly traded companies, including those in the healthcare sector. While specific grant sizes vary based on company size, performance, and individual roles, the use of restricted stock with a vesting period is a standard mechanism to align director interests with long-term company performance.
• Similar practices are observed at peers like UnitedHealth Group or CVS Health, where directors and executives receive equity awards tied to future performance or service to ensure sustained commitment and performance.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of a director's interests with long-term company performance and value creation.
• Employees: The 2024 Equity Incentive Plan, under which these shares were granted, may also benefit other employees, fostering a sense of shared ownership and incentivizing performance across the organization.

Next Steps

• Vesting of 4,525 restricted shares on the earlier of June 10, 2027, or the date of the Issuer's 2027 annual meeting of stockholders.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction involving a restricted stock grant to a director. While it signals continued alignment of interests, it does not provide new fundamental information about the company's operational or financial performance that would warrant a change in investment recommendation. Investors should continue to hold and monitor broader company performance and market conditions.

Keywords

Astrana Health, ASTH, Form 4, Insider Transaction, Restricted Stock, Equity Incentive Plan, Director Compensation, Weili Dai